Day One Biopharmaceuticals, Inc. - Common Stock (DAWN)
11.71
-0.16 (-1.35%)
Day One Biopharmaceuticals Inc is a biotechnology company focused on developing innovative therapies for patients with serious diseases, particularly in the field of oncology
The company is dedicated to creating targeted treatments for pediatric and adult patients, with an emphasis on precision medicine that addresses the specific genetic and molecular characteristics of their cancers. By leveraging advanced science and a deep understanding of cancer biology, Day One aims to deliver effective, safe, and impactful therapeutic options, improving the lives of patients facing difficult-to-treat conditions.
DAWN stock results show that Day One Biopharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting protein-tyrosine kinase 7 candidate to Day One Biopharma.
The Dow Jones Industrial Average is building on this morning's gains, up 343 points at last look, while the S&P 500 and Nasdaq Composite sit firmly in the black as well.
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.
Gainers Forza X1, Inc. (NASDAQFRZA) shares rose 85.6% to $2.32 in pre-market trading after the company tweeted Friday 'Get ready for something extraordinary! Stay tuned!'
Gainers Sono Group N.V. (NYSESEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.
